| scholarly article | Q13442814 |
| P2093 | author name string | Antiretroviral Therapy Cohort Collaboration | |
| P2860 | cites work | Factors Influencing Increases in CD4 Cell Counts of HIV‐Positive Persons Receiving Long‐Term Highly Active Antiretroviral Therapy | Q57181194 |
| When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies | Q57181234 | ||
| Rising HIV-related mortality in young Americans | Q57555633 | ||
| Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ L in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy | Q58075270 | ||
| Relations among CD4 Lymphocyte Count Nadir, Antiretroviral Therapy, and HIV-1 Disease Progression: Results from the EuroSIDA Study | Q59297243 | ||
| Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens | Q24534391 | ||
| Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy | Q30947115 | ||
| Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians | Q33910613 | ||
| Decline in the AIDS and death rates in the EuroSIDA study: an observational study | Q33967061 | ||
| Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study | Q33989047 | ||
| Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies | Q34139859 | ||
| Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies | Q34228103 | ||
| CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study | Q34269641 | ||
| A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team | Q34438252 | ||
| Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count | Q34548243 | ||
| Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users | Q36065237 | ||
| Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study | Q36247045 | ||
| Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies | Q36285986 | ||
| Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users | Q38503675 | ||
| Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion | Q40346109 | ||
| Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. | Q40433154 | ||
| Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy | Q44300131 | ||
| Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy | Q44404808 | ||
| Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. | Q45161155 | ||
| Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study | Q45413375 | ||
| Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. | Q45937663 | ||
| Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries | Q46391119 | ||
| Study of 2708 heroin-related deaths in north-eastern Italy 1985-98 to establish the main causes of death. | Q50680029 | ||
| Expanded screening for HIV in the United States--an analysis of cost-effectiveness. | Q50756519 | ||
| Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. | Q51986206 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | collaboration | Q1145523 |
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 607-615 | |
| P577 | publication date | 2007-12-01 | |
| P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
| P1476 | title | Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients | |
| P478 | volume | 46 |
| Q38438589 | All-cause and HIV-related mortality rates among HIV-infected patients after initiating highly active antiretroviral therapy: the impact of Aboriginal ethnicity and injection drug use. |
| Q30372724 | CD4 immunophenotyping in HIV infection. |
| Q37001718 | Causes of death and risk factors for mortality among HIV-infected patients receiving antiretroviral therapy in Korea |
| Q34354340 | Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09 |
| Q33736040 | Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). |
| Q46959264 | Cohort profile: the Swiss HIV Cohort study |
| Q33916355 | Cost-effectiveness of HIV screening in STD clinics, emergency departments, and inpatient units: a model-based analysis |
| Q37189075 | Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial |
| Q43925184 | Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study |
| Q34321843 | Evolution of HIV treatment guidelines in high- and low-income countries: converging recommendations |
| Q84420336 | Five-year outcomes of the China National Free Antiretroviral Treatment Program |
| Q39548551 | Foreign-born status as a predictor of engagement in HIV care in a large US metropolitan health system |
| Q64094006 | Improvements in the HIV care continuum needed to meaningfully reduce HIV incidence among men who have sex with men in Baltimore, US: a modelling study for HPTN 078 |
| Q24597052 | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies |
| Q44324472 | Morbidity and mortality in HIV infection |
| Q35057962 | Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries |
| Q34851665 | Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy |
| Q33634206 | One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: data from a veteran cohort |
| Q37028220 | Predictors of clinical progression in HIV-1-infected adults initiating combination antiretroviral therapy with advanced disease in the Asia-Pacific region: results from the TREAT Asia HIV observational database |
| Q40075594 | Prognosis of HIV Patients Receiving Antiretroviral Therapy According to CD4 Counts: A Long-term Follow-up study in Yunnan, China. |
| Q35962516 | The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis |
| Q24656950 | Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies |
| Q46423547 | Welfare Homes for Patients Living with HIV/AIDS in Andalusia |
Search more.